Japanese officials have a approved the medical CBD brand Epidiolex for clinical trials, marking the first time such products have been approved by the Japanese government. The trials, to be
Japanese officials approve Epidiolex for clinical trials Read More »
A World Health Organization (WHO) Committee has delayed until January its review of the global legal status of cannabis, which was expected to be delivered during a meeting last week
WHO committee delays review on global status of cannabis Read More »
An ex-doctor in Australia has successfully defended himself in a landmark medical cannabis trial, arguing that his unauthorized treatments with cannabis compounds were of “medical necessity” to the patients he
Ex-doctor found innocent in Australian cannabis treatment case Read More »
Cannabis, activists, scientists, practitioners and other stakeholders will make presentations at the International Cannabis Policy Conference Dec. 7-9 in Vienna. Some 20 speakers representing 11 countries will talk about subjects
Global cannabis stakeholders will descend on Vienna in December Read More »
Denver, Colorado-based Elixinol Global Limited today debuted on the OTCQX Best Market in the USA just ahead of anticipated changes in federal legislation that could supercharge the CBD sector. Elixinol,
Elixinol debuts on U.S. exchange as Farm Bill vote looms Read More »
Despite significant institutional challenges, the European CBD market will see strong growth for those companies that can navigate the murky waters of EU regulation while managing growth in a fast
Euro CBD market will grow; look for some shakeout globally Read More »
Insured patients in the USA would pay up to $200 per month for CBD-based drug Epidiolex under a recent pricing announcement from the maker, UK-based GW Pharmaceuticals. Epidiolex is the
GW Pharma releases pricing on newly approved CBD-drug Read More »
The monopoly on medical knowledge previously held by governments, pharma companies and the medical establishment has now been broken forever due to technological advancements and the internet, according to Boaz
”Democratization of knowledge” will drive demand and data about medical cannabis Read More »
Health care needs to eschew a high-tech approach and go beyond the treatment of symptoms to attack the causes of chronic diseases rooted in current lifesyles. That’s the message Paulius
Reps from 10 countries will talk CBD at HT’s August biz meet-up Read More »
Recent approval of GW Pharmaceutical’s cannabidiol-based drug Epidiolex in the United States not only will soon give patients needed relief, but can spur further research into cannabinoids as well as
After approval of first cannabis-based drug in USA, what’s next? Read More »
